TQB3201, a PROTAC drug targeting the Androgen Receptor (AR), is positioned to address unmet needs in advanced prostate cancer treatment, particularly in patients resistant to current therapies like abiraterone and enzalutamide. The market for advanced prostate cancer therapies is expanding, with increasing demand for innovative treatments that can overcome resistance mechanisms. Given the competitive landscape, TQB3201's unique mechanism of action may provide a significant advantage, potentially leading to a strong market position if clinical efficacy is demonstrated. Diligence should focus on the competitive landscape, particularly other emerging therapies targeting AR and the potential for partnerships or licensing agreements to enhance market entry and distribution.